The multidisciplinary European consortium MARVAX will receive 7.4 million euros over the next four years for the research and development of vaccines against Marburg viruses.
Researchers from France, Spain and Germany will develop novel vaccine candidates, which will be tested in preclinical animal models and bring them to the stage where they are ready for phase I clinical trials.
The Bernhard Nocht Institute for Tropical Medicine (BNITM, Germany) will coordinate the MARVAX consortium that also includes the Institut Pasteur (France), the National Centre for Biotechnology of the Spanish National Research Council (CNB-CSIC, Spain), and CZ Vaccines (Zendal group, Spain).
Deadly pathogen
The Marburg virus is one of the most dangerous pathogens for humans. According to the World Health Organization (WHO), the mortality rate ranges between 24% and 88%, depending on the strain of the virus and the quality of the medical care. Like Ebola virus, it is an RNA virus of the filovirus family.
The first cases of the Marburg virus disease were documented in 1967. Since then, there have been several outbreaks in eastern, central and southern Africa. In 2021 for the first time the virus emerged in West Africa and this year in Tanzania and Equatorial Guinea.
Marburg virus disease is a zoonosis as the initial transmission usually comes from animals: the natural hosts of this virus are presumably fruit bats. Marburg virus is transmitted between humans through body fluids, possibly also through semen.
Vaccine pipeline
To date, there are no effective antiviral drugs or vaccines, and Marburg virus disease can only be treated supportively. Therefore, any epidemic causes unacceptable suffering in the affected countries and has the potential to further spread the virus. Thus, development of treatments or vaccines are needed.
Two vaccines against Marburg viruses are currently in Phase I clinical trials. However, they only target a single antigen of the virus. This could impair their protective effect. Thus, exploring new strategies, the MARVAX consortium will develop novel vaccine candidates based on two different viral vectors that will express multiple Marburg virus antigens. Both combined approaches are expected to maximise the immunogenicity and protective effect of the vaccine candidates.
Above all, the MARVAX consortium is joining forces with experts in vaccine development and production, virology, and immunology to go significantly beyond previous research approaches.
The novel vaccine candidates against Marburg viruses will be generated by the CSIC National Centre for Biotechnology (CNB-CSIC) and the Institut Pasteur, and their immunogenicity and efficacy will be evaluated in animal models by BNITM, CNB-CSIC and Institut Pasteur in close collaboration. CZ vaccines will develop the manufacturing process and generate clinical batches of the best-in-class vaccines that will be ready for future phase I clinical trials.
More frequent outbreaks
”I am very pleased that we were able to convince the European Commission with our study concept,” says Prof. César Muñoz-Fontela, head of the Virus Immunology research group at the BNITM and MARVAX project coordinator. ”Marburg virus outbreaks are becoming more frequent and more and more countries are affected. We must finally develop effective vaccines in order to contain outbreaks at an early stage with the help of ring vaccinations, as we did with Ebola, and put an end to the deaths!”
The MARVAX study platform will receive a Horizon Europe grant of 7.4 million euros from the European Framework Programme for Research and Innovation over the next four years. The MARVAX consortium includes the Institut Pasteur (France), the Spanish National Research Council (Spain), the BNITM (Germany) and CZ Vaccines (Spain). The platform studies included in the MARVAX consortium will be carried out in close co-operation with the WHO. This should also ensure that a rapid response is possible in the event of renewed Marburg virus outbreaks.
No comments yet